Streetbeat News

Products Services

MLTX

MoonLake Immunotherapeutics announced 24-week top-line results from its global Phase 2 MIRA trial for its maintenance treatment with its Nanobody® Sonelokimab. The company is expected to be mentioned as MLTX in the article.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:00 am

GOOG

GOOGL

Elon Musk criticized the increasing number of advertisements on Alphabet Inc.-owned YouTube, terming it as 'Ad Creep'. This criticism comes amidst YouTube's decision to limit individual ad control options for creators and adjust its ad format. YouTube also plans to increase the price for YouTube Premium to $13.99 per month.

Portfolio Pulse from Ananya Gairola

October 16, 2023 | 6:58 am

ERJ

HON

Honeywell (HON) has successfully tested an engine using 100% sustainable aviation fuel on an Embraer (ERJ) business jet. This marks a significant step towards sustainable aviation.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:52 am

IMUX

Immunic has presented data from its Phase 1b clinical trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:49 am

MREO

RARE

Ultragenyx and Mereo BioPharma have announced interim Phase 2 data from their Phase 2/3 Orbit study. The data shows that Setrusumab significantly reduced fracture rates in patients with Osteogenesis Imperfecta.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:41 am

AAPL

Apple Inc. is rumored to be launching updates to its iPad lineup this week, including updated versions of the iPad Air, iPad mini, and the entry-level iPad. The iPad Air is expected to be powered by the M2 chip, replacing the current M1 chip, and the iPad mini will feature the A16 Bionic chip. The company is also expected to address the 'jelly scrolling' issue found in the iPad mini.

Portfolio Pulse from Benzinga Neuro

October 16, 2023 | 6:36 am

COGT

Cogent Biosciences has presented updated preclinical data from its next-generation selective Fibroblast Growth Factor Receptor 2 (FGFR2) program at the 2023 AACR-NCI-EORTC International Conference.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:35 am

VSTM

Verastem Oncology has announced initial results of the RAMP 203 trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer. The results could have significant implications for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:32 am

CHRS

Coherus has announced data on Toripalimab at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:30 am

BDTX

Black Diamond Therapeutics has presented dose escalation data from its Phase 1 trial of BDTX-1535, demonstrating durable responses in patients with non-small cell lung cancer (NSCLC). The data was presented at the AACR-NCI-EORTC International Conference.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:28 am